- Conditions
- Pneumonia, Bacterial, Pneumonia, Viral, Pneumonia Fungal, Pneumonia Cavitary, Immunocompromised Host
- Interventions
- Karius Test
- Diagnostic Test
- Lead sponsor
- Karius, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 257 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 10
- States / cities
- Duarte, California • San Francisco, California • Aurora, Colorado + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Invasive Fungal Infections
- Interventions
- fosmanogepix
- Drug
- Lead sponsor
- Basilea Pharmaceutica
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 6
- States / cities
- Duarte, California • Durham, North Carolina
- Conditions
- Pneumonia, Bacterial
- Interventions
- 13C-urea breath test
- Device
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Community-acquired Pneumonia, Bacterial Pneumonia
- Interventions
- CMTX-101, Placebo
- Drug
- Lead sponsor
- Clarametyx Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 8
- States / cities
- Augusta, Georgia • Idaho Falls, Idaho • Louisville, Kentucky + 5 more
- Conditions
- Pneumonia, Bacterial, Pneumonia Childhood, Urinary Tract Infections, Soft Tissue Infections, Skin Infections, Community-acquired Pneumonia
- Interventions
- Discharge antibiotic stewardship intervention
- Behavioral
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 28 Days to 18 Years
- Enrollment
- 1,131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 5
- States / cities
- St Louis, Missouri • Philadelphia, Pennsylvania • Salt Lake City, Utah + 1 more
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Pentamidine isethionate, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1992
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Covid19, Aspergillosis, Fungal Infection
- Interventions
- Observation to monitor patients for these infections
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Sitamaquine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1993
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Baltimore, Maryland
- Conditions
- Pneumonia, Pneumonia, Viral, Pneumonia, Bacterial
- Interventions
- Electronic alert, Structured communication of test results
- Behavioral
- Lead sponsor
- Jonathan Baghdadi
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Bacterial Infections, Intra-Abdominal Infection, Pneumonia, Bacterial, Skin Diseases, Bacterial, Skin Diseases, Infectious
- Interventions
- Tygacil
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 8 Years to 11 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 18
- States / cities
- Long Beach, California • Oakland, California • Orange, California + 15 more
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Atovaquone
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 1 Day and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Research Triangle Park, North Carolina
- Conditions
- Pseudomonas Aeruginosa
- Interventions
- MEDI3902, Placebo
- Drug · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 8
- States / cities
- Englewood, Colorado • Gainesville, Florida • Atlanta, Georgia + 5 more
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Pentamidine isethionate
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Month to 6 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1996
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Oakland, California • Washington D.C., District of Columbia + 4 more
- Conditions
- Pneumonia, Pneumococcal, Vaccines, Pneumococcal
- Interventions
- Urine sample collection
- Procedure
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 782 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 14
- States / cities
- Mobile, Alabama • La Mesa, California • Tampa, Florida + 9 more
- Conditions
- Pneumocystis Jirovecii Infection, Pneumocystis, Cryptococcosis, Candidiasis, Aspergillosis
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12,032 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
- Interventions
- AFX3772, Prevnar 13, Prevnar 20
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 42 Days to 90 Days
- Enrollment
- 388 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 42
- States / cities
- Jonesboro, Arkansas • Los Angeles, California • Miami, Florida + 35 more
- Conditions
- Pneumonia, Bacterial
- Interventions
- tigecycline, imipenem/cilastatin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 3
- States / cities
- Louisville, Kentucky • Omaha, Nebraska • Morgantown, West Virginia
- Conditions
- Pneumococcal Vaccines
- Interventions
- 0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20, 0.5 mL of the High-PFS dose VAX-31
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 45
- States / cities
- Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 32 more
- Conditions
- Sinusitis, Bronchitis, Chronic, Pneumonia, Bacterial
- Interventions
- all macrolide antibiotics, all beta-lactam antibiotics
- Drug
- Lead sponsor
- CPL Associates
- Other
- Eligibility
- Up to 95 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Spokane, Washington
- Conditions
- Pneumonia
- Interventions
- Murepavadin, Two anti-pseudomonal antibiotics
- Drug
- Lead sponsor
- Polyphor Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Springfield, Missouri • Greensboro, North Carolina
- Conditions
- Pneumococcal Vaccines
- Interventions
- 31 valent pneumococcal conjugate vaccine, PCV20, PCV21
- Biological
- Lead sponsor
- Vaxcyte, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,049 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Chinle, Arizona • Whiteriver, Arizona + 27 more
- Conditions
- Cystic Fibrosis
- Interventions
- Cysteamine, Placebo Oral Capsule
- Drug
- Lead sponsor
- NovaBiotics Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • San Francisco, California • Gainesville, Florida + 5 more
- Conditions
- Community-acquired Bacterial Pneumonia
- Interventions
- Solithromycin, Moxifloxacin
- Drug
- Lead sponsor
- Melinta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 863 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 62
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Chino, California + 53 more